Lyra Therapeutics (LYRA) Cash from Investing Activities (2019 - 2025)
Quarterly Cash from Investing Activities fell 100.34% to -$96000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.2 million through Dec 2025, down 54.95% year-over-year, with the annual reading at -$98000.0 for FY2025, 100.12% down from the prior year.
Lyra Therapeutics' Cash from Investing Activities history spans 7 years, with the latest figure at -$96000.0 for Q4 2025.
- Cash from Investing Activities came in at -$96000.0 for Q4 2025, down from $28.1 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $36.2 million in Q2 2024 to a low of -$64.9 million in Q4 2022.
- The 5-year median for Cash from Investing Activities is -$96000.0 (2025), against an average of -$45058.8.
- Year-over-year, Cash from Investing Activities crashed 51551.72% in 2023 and then surged 6548.48% in 2024.
- Lyra Therapeutics' Cash from Investing Activities stood at -$1.1 million in 2021, then tumbled by 5889.84% to -$64.9 million in 2022, then soared by 96.36% to -$2.4 million in 2023, then surged by 1292.5% to $28.1 million in 2024, then crashed by 100.34% to -$96000.0 in 2025.
- Per Business Quant, the three most recent readings for LYRA's Cash from Investing Activities are -$96000.0 (Q4 2025), $28.1 million (Q4 2024), and $8.1 million (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -428.90 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Lyra Therapeutics | - | - | - | -96,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -96,000.00 |
| Dec 31, 2025 | -96,000.00 |
| Dec 31, 2024 | 28.13 Mn |
| Dec 31, 2024 | 28.13 Mn |
| Sep 30, 2024 | 8.14 Mn |
| Sep 30, 2024 | 8.14 Mn |
| Jun 30, 2024 | 36.18 Mn |
| Jun 30, 2024 | 36.18 Mn |
| Mar 31, 2024 | 7.86 Mn |
| Mar 31, 2024 | 7.86 Mn |
| Dec 31, 2023 | -2.36 Mn |
| Dec 31, 2023 | -2.36 Mn |
| Sep 30, 2023 | -14.98 Mn |
| Sep 30, 2023 | -14.98 Mn |
| Jun 30, 2023 | -561,000.00 |
| Jun 30, 2023 | -561,000.00 |
| Mar 31, 2023 | 5.32 Mn |
| Mar 31, 2023 | 5.32 Mn |
| Dec 31, 2022 | -64.87 Mn |
| Dec 31, 2022 | -64.87 Mn |
| Sep 30, 2022 | -29,000.00 |
| Sep 30, 2022 | -29,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | -93,000.00 |
| Mar 31, 2022 | -93,000.00 |
| Dec 31, 2021 | -1.08 Mn |
| Dec 31, 2021 | -1.08 Mn |
| Sep 30, 2021 | -517,000.00 |
| Sep 30, 2021 | -517,000.00 |
| Jun 30, 2021 | -625,000.00 |
| Jun 30, 2021 | -625,000.00 |
| Mar 31, 2021 | -1.16 Mn |
| Mar 31, 2021 | -1.16 Mn |
| Dec 31, 2020 | -1.10 Mn |
| Dec 31, 2020 | -1.10 Mn |
| Sep 30, 2020 | -589,000.00 |
| Sep 30, 2020 | -589,000.00 |
| Jun 30, 2020 | -77,000.00 |
| Jun 30, 2020 | -77,000.00 |
| Mar 31, 2020 | -8,000.00 |
| Mar 31, 2020 | -8,000.00 |
| Dec 31, 2019 | -80,000.00 |
| Dec 31, 2019 | -80,000.00 |
| Sep 30, 2019 | -10,000.00 |
| Sep 30, 2019 | -10,000.00 |
| Jun 30, 2019 | -69,000.00 |
| Jun 30, 2019 | -69,000.00 |
| Mar 31, 2019 | -52,000.00 |
| Mar 31, 2019 | -52,000.00 |